Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

08 February 2021

First Patient dosed in Phase I/II Clinical Study of PD-L1/CTLA-4 Bispecific Antibody KN046 in Combination with Donafenib For the Treatment of Advanced & Metastatic Hepatocellular Carcinoma（HCC） Aiming to evaluate the safety, tolerability and efficacy of KN046 in combination with Donafenib in patients with advanced & metastatic hepatocellular carcinoma(HCC).
01 February 2021

Data from Two Clinical Studies of PD-L1/CTLA-4 bispecific antibody KN046 presented at the 21st World Conference on Lung Cancer (WCLC 2020) The Phase III pivotal clinical trial of KN046 as first-line treatment of squamous NSCLC (ENREACH-LUNG-01) and the Phase II international registration clinical trial for the treatment of advanced thymi...
19 Janurary 2021

NMPA Grants Priority Review to the BLA for Envafolimab(KN035) As the world's first subcutaneous PD-(L)1 inhibitor,Envafolimab could be an innovative treatment option for cancer patients and improve their quality of life.
18 Janurary 2021

The preliminary clinical efficacy and safety of KN046 plus chemo-radiation therapy in recurrent and metastatic esophageal squamous cell carcinoma presented at ASCO GI We look forward to seeing more positive data and ultimately enhancing the treatment effect and improving the patients' quality of lives who with esophageal cancer in China and the world.
15 Janurary 2021

Alphamab Oncology Announced First Patient dosed in ENREACH-Thymic – A Phase Ⅱ Registration Clinical Study of KN046 for the Treatment of Advanced Thymic Carcinoma Dosing of the first patient in this Phase II registration study is another important milestone in the global development for KN046. We expect that this innovative therapeutics become a breakthrough th...
06 Janurary 2021

Alphamab Oncology wins the "Most Valuable Medical and Pharmaceutical Company " at “The 5th Annual Awards Ceremony of Hong Kong Golden Stock” Alphamab Oncology is winning of this award demonstrates the industry's attention and recognition of the company's R&D and operation advantages, and it also affirms the company's long-te...
30 December 2020

Alphamab Oncology is officially included in Southbound Stock Connect This means that mainland institutional investors and individuals who meet the conditions can purchase Alphamab Oncology shares through Southbound Connect.
28 December 2020

IND Approval for Combination Therapy anti-HER2 bispecific antibody KN026 and Ibrance® (palbociclib) As a potential chemotherapy-free regimen, the trial will bring new hope to patients with HER2-positive breast cancer.
28 December 2020

Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology is developing COVID-19 Multispecific Neutralizing Antibody It is expected to provide a new and effective therapeutic drug option for the treatment of the COVID-19.
23 December 2020

Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the combination therapy of KN026 plus KN046 for the treatment of gastric cancer, including cancer of the gastroesophageal junction This is the third ODD granted to Alphamab Oncology by FDA.

15 16 17 18 19 20 21